Coherus Oncology (CHRS) Treasury Shares (2012 - 2025)

Coherus Oncology has disclosed Treasury Shares across 11 years of filings, most recently posting $188557.0 for Q4 2025.

• Treasury Shares for Q4 2025 came in at $188557.0, down 75.46% year-over-year; the trailing twelve-month figure through Dec 2025 was $188557.0 (down 75.46% YoY), and the FY2025 annual result was $188557.0, down 75.46% from the prior year.
• Treasury Shares came in at $188557.0 for Q4 2025 at Coherus Oncology, down from $768237.0 in the prior quarter.
• In the past five years, Treasury Shares ranged from a high of $2.3 million in Q4 2022 to a low of $188557.0 in Q4 2025.
• The 5-year median for Treasury Shares is $1.7 million (2023), against an average of $1.4 million.
• Across the five-year window, Treasury Shares jumped 82.61% in 2021 and slumped 75.46% in 2025, its largest moves.
• Coherus Oncology's Treasury Shares stood at $1.8 million in 2021, then increased by 26.55% to $2.3 million in 2022, then declined by 26.0% to $1.7 million in 2023, then sank by 55.51% to $768237.0 in 2024, then plunged by 75.46% to $188557.0 in 2025.
• The last three Treasury Shares figures came in at $188557.0 (Q4 2025), $768237.0 (Q4 2024), and $1.7 million (Q4 2023), per Business Quant data.